Melanie Jefferson1,2, Richard R Drake3,1, Michael Lilly1,4, Stephen J Savage1,5, Sarah Tucker Price6, Chanita Hughes Halbert1,2. 1. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC. 2. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC. 3. Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC. 4. Department of Medicine, Medical University of South Carolina, Charleston, SC. 5. Department of Urology, Medical University of South Carolina, Charleston, SC. 6. Department of Family Medicine, Medical University of South Carolina, Charleston, SC.
Abstract
Objective: To characterize rates of co-morbidity among prostate cancer patients treated with radical prostatectomy and to examine the association between co-morbidity status and race, clinical factors, and health behaviors for cancer control. Design/Study Participants: Retrospective cohort study among prostate cancer patients treated with radical prostatectomy. Setting: Academic medical center located in the southeastern region of the United States. Main Outcome Measure: Patients with at least one of five co-morbid conditions considered were categorized as having a co-morbidity, and those without any were categorized as not having a co-morbid condition. Co-morbid conditions considered were hypertension, diabetes, heart problems, stroke, and high cholesterol, which had been recorded in the electronic medical record as part of their past medical history. Results: Fifty-one percent of participants had a co-morbidity, with hypertension being the most common. The average number of co-morbidities among study participants was .87. In a multivariate logistic regression analysis, being diagnosed with prostate cancer within the past four years was associated with an increased likelihood of having a co-morbidity (OR=4.71, 95% CI=2.69, 8.25, P=.0001) compared with diagnosis five or more years ago. Age was also associated with an increased likelihood of having a co-morbidity (OR=1.30, 95% CI=1.005, 1.68, P=.05). In this study cohort, race, stage at diagnosis, and PSA level were not statistically associated with co-morbidity status. Conclusion: Better chronic disease management is needed among prostate cancer survivors through more effective survivorship care planning and interventions that promote health behaviors.
Objective: To characterize rates of co-morbidity among prostate cancerpatients treated with radical prostatectomy and to examine the association between co-morbidity status and race, clinical factors, and health behaviors for cancer control. Design/Study Participants: Retrospective cohort study among prostate cancerpatients treated with radical prostatectomy. Setting: Academic medical center located in the southeastern region of the United States. Main Outcome Measure: Patients with at least one of five co-morbid conditions considered were categorized as having a co-morbidity, and those without any were categorized as not having a co-morbid condition. Co-morbid conditions considered were hypertension, diabetes, heart problems, stroke, and high cholesterol, which had been recorded in the electronic medical record as part of their past medical history. Results: Fifty-one percent of participants had a co-morbidity, with hypertension being the most common. The average number of co-morbidities among study participants was .87. In a multivariate logistic regression analysis, being diagnosed with prostate cancer within the past four years was associated with an increased likelihood of having a co-morbidity (OR=4.71, 95% CI=2.69, 8.25, P=.0001) compared with diagnosis five or more years ago. Age was also associated with an increased likelihood of having a co-morbidity (OR=1.30, 95% CI=1.005, 1.68, P=.05). In this study cohort, race, stage at diagnosis, and PSA level were not statistically associated with co-morbidity status. Conclusion: Better chronic disease management is needed among prostate cancer survivors through more effective survivorship care planning and interventions that promote health behaviors.
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Chanita Hughes Halbert; Scarlett Bellamy; Vanessa Briggs; Ernestine Delmoor; Joseph Purnell; Rodney Rogers; Benita Weathers; Jerry C Johnson Journal: Health Educ Res Date: 2017-06-01
Authors: Claire F Snyder; Kevin D Frick; Robert J Herbert; Amanda L Blackford; Bridget A Neville; Klaus W Lemke; Michael A Carducci; Antonio C Wolff; Craig C Earle Journal: J Cancer Surviv Date: 2015-02-26 Impact factor: 4.442
Authors: Fan Ye; Dominic H Moon; William R Carpenter; Bryce B Reeve; Deborah S Usinger; Rebecca L Green; Kiayni Spearman; Nathan C Sheets; Kevin A Pearlstein; Angela R Lucero; Mark R Waddle; Paul A Godley; Ronald C Chen Journal: JAMA Oncol Date: 2017-08-01 Impact factor: 31.777
Authors: Christopher J D Wallis; Giacomo Novara; Laura Marandino; Axel Bex; Ashish M Kamat; R Jeffrey Karnes; Todd M Morgan; Nicolas Mottet; Silke Gillessen; Alberto Bossi; Morgan Roupret; Thomas Powles; Andrea Necchi; James W F Catto; Zachary Klaassen Journal: Eur Urol Date: 2020-05-03 Impact factor: 20.096